Colorectal Cancer - Pipeline Review, H1 2014 - KMPH FOX 26 | Central San Joaquin Valley News Source

Colorectal Cancer - Pipeline Review, H1 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, June 12, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Colorectal Cancer - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/diseases/colorectal_cancer_pipeline_review_h1_2013.html

Colorectal Cancer - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Colorectal Cancer - Pipeline Review, H1 2014', provides an overview of the Colorectal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer

- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in the therapeutics development for Colorectal Cancer and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop strategic initiatives by understanding the focus areas of leading companies

- Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
Introduction 8
Colorectal Cancer Overview 9
Therapeutics Development 10
Colorectal Cancer - Therapeutics under Development by Companies 12
Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 23
Colorectal Cancer - Pipeline Products Glance 26
Colorectal Cancer - Products under Development by Companies 30
Colorectal Cancer - Products under Investigation by Universities/Institutes 41
Colorectal Cancer - Companies Involved in Therapeutics Development 42
Colorectal Cancer - Therapeutics Assessment 151
Drug Profiles 170
Colorectal Cancer - Recent Pipeline Updates 463
Colorectal Cancer - Dormant Projects 569
Colorectal Cancer - Discontinued Products 580
Colorectal Cancer - Product Development Milestones 583
Appendix 591

List of Tables

Number of Products under Development for Colorectal Cancer, H1 2014 31
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2014 32
Number of Products under Development by Companies, H1 2014 34
Number of Products under Development by Companies, H1 2014 (Contd..1) 35
Number of Products under Development by Companies, H1 2014 (Contd..2) 36
Number of Products under Development by Companies, H1 2014 (Contd..3) 37
Number of Products under Development by Companies, H1 2014 (Contd..4) 38
Number of Products under Development by Companies, H1 2014 (Contd..5) 39
Number of Products under Development by Companies, H1 2014 (Contd..6) 40
Number of Products under Development by Companies, H1 2014 (Contd..7) 41
Number of Products under Development by Companies, H1 2014 (Contd..8) 42
Number of Products under Development by Companies, H1 2014 (Contd..9) 43
Number of Products under Investigation by Universities/Institutes, H1 2014 45
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 46
Comparative Analysis by Late Stage Development, H1 2014 47
Comparative Analysis by Clinical Stage Development, H1 2014 48
Comparative Analysis by Early Stage Development, H1 2014 49
Comparative Analysis by Unknown Stage Development, H1 2014 50
Products under Development by Companies, H1 2014 51
Products under Development by Companies, H1 2014 (Contd..1) 52
Products under Development by Companies, H1 2014 (Contd..2) 53
Products under Development by Companies, H1 2014 (Contd..3) 54
Products under Development by Companies, H1 2014 (Contd..4) 55
Products under Development by Companies, H1 2014 (Contd..5) 56
Products under Development by Companies, H1 2014 (Contd..6) 57
Products under Development by Companies, H1 2014 (Contd..7) 58
Products under Development by Companies, H1 2014 (Contd..8) 59
Products under Development by Companies, H1 2014 (Contd..9) 60
Products under Development by Companies, H1 2014 (Contd..10) 61
Products under Investigation by Universities/Institutes, H1 2014 62
Colorectal Cancer - Pipeline by Amgen Inc., H1 2014 63
Colorectal Cancer - Pipeline by Adherex Technologies Inc., H1 2014 64
Colorectal Cancer - Pipeline by AstraZeneca PLC, H1 2014 65
Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2014 66
Colorectal Cancer - Pipeline by Viralytics Ltd, H1 2014 67
Colorectal Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 68
Colorectal Cancer - Pipeline by Genentech, Inc., H1 2014 69
Colorectal Cancer - Pipeline by Gilead Sciences, Inc., H1 2014 70
Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2014 71
Colorectal Cancer - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 72
Colorectal Cancer - Pipeline by Oxford BioMedica plc, H1 2014 73
Colorectal Cancer - Pipeline by Aposense Ltd., H1 2014 74
Colorectal Cancer - Pipeline by Novartis AG, H1 2014 75
Colorectal Cancer - Pipeline by Aphios Corporation, H1 2014 76
Colorectal Cancer - Pipeline by Astellas Pharma Inc., H1 2014 77
Colorectal Cancer - Pipeline by CK Life Sciences Int'l., (Holdings) Inc., H1 2014 78
Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2014 79
Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 80
Colorectal Cancer - Pipeline by Pfizer Inc., H1 2014 81
Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 82
Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 83
Colorectal Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 84
Colorectal Cancer - Pipeline by Bayer AG, H1 2014 85
Colorectal Cancer - Pipeline by Advaxis, Inc., H1 2014 86
Colorectal Cancer - Pipeline by 4SC AG, H1 2014 87
Colorectal Cancer - Pipeline by EntreMed, Inc., H1 2014 88
Colorectal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2014 89
Colorectal Cancer - Pipeline by Enzo Biochem, Inc., H1 2014 90
Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2014 91
Colorectal Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 92
Colorectal Cancer - Pipeline by MEI Pharma, Inc., H1 2014 93
Colorectal Cancer - Pipeline by Compugen Ltd., H1 2014 94
Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2014 95
Colorectal Cancer - Pipeline by CytRx Corporation, H1 2014 96
Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 97
Colorectal Cancer - Pipeline by Dendreon Corporation, H1 2014 98
Colorectal Cancer - Pipeline by LG Life Sciences, Ltd., H1 2014 99
Colorectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2014 100
Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2014 101
Colorectal Cancer - Pipeline by CrystalGenomics, Inc., H1 2014 102
Colorectal Cancer - Pipeline by Microbio Co., Ltd., H1 2014 103
Colorectal Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014 104
Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2014 105
Colorectal Cancer - Pipeline by Isarna Therapeutics GmbH, H1 2014 106
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2014 107
Colorectal Cancer - Pipeline by CIMAB S.A., H1 2014 108
Colorectal Cancer - Pipeline by Supratek Pharma Inc., H1 2014 109
Colorectal Cancer - Pipeline by Fusion Antibodies Ltd, H1 2014 110
Colorectal Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2014 111
Colorectal Cancer - Pipeline by Multimmune GmbH, H1 2014 112
Colorectal Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 113
Colorectal Cancer - Pipeline by Glycotope GmbH, H1 2014 114
Colorectal Cancer - Pipeline by TheRyte Ltd., H1 2014 115
Colorectal Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2014 116
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2014 117
Colorectal Cancer - Pipeline by Cellectis S.A., H1 2014 118
Colorectal Cancer - Pipeline by MacroGenics, Inc., H1 2014 119
Colorectal Cancer - Pipeline by Boston Biomedical, Inc., H1 2014 120
Colorectal Cancer - Pipeline by PLx Pharma Inc., H1 2014 121
Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2014 122
Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 123
Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 124
Colorectal Cancer - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 125
Colorectal Cancer - Pipeline by MolMed S.p.A., H1 2014 126
Colorectal Cancer - Pipeline by Etubics Corporation, H1 2014 127
Colorectal Cancer - Pipeline by Xcovery, Inc., H1 2014 128
Colorectal Cancer - Pipeline by Quintessence Biosciences, Inc., H1 2014 129
Colorectal Cancer - Pipeline by WntResearch AB, H1 2014 130
Colorectal Cancer - Pipeline by 3-V Biosciences, Inc., H1 2014 131
Colorectal Cancer - Pipeline by Phenomenome Discoveries, Inc., H1 2014 132
Colorectal Cancer - Pipeline by Interprotein Corporation, H1 2014 133
Colorectal Cancer - Pipeline by Zyngenia, Inc., H1 2014 134
Colorectal Cancer - Pipeline by Recepta Biopharma S.A., H1 2014 135
Colorectal Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2014 136
Colorectal Cancer - Pipeline by Pepscan Therapeutics, H1 2014 137
Colorectal Cancer - Pipeline by NuCana BioMed Limited, H1 2014 138
Colorectal Cancer - Pipeline by KAEL-GemVax Co., Ltd., H1 2014 139
Colorectal Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 140
Colorectal Cancer - Pipeline by XBiotech USA, Inc., H1 2014 141
Colorectal Cancer - Pipeline by Wellstat Biologics Corporation, H1 2014 142
Colorectal Cancer - Pipeline by Regulon Inc., H1 2014 143
Colorectal Cancer - Pipeline by Gradalis Inc., H1 2014 144
Colorectal Cancer - Pipeline by Mabion SA, H1 2014 145
Colorectal Cancer - Pipeline by SentoClone International AB, H1 2014 146
Colorectal Cancer - Pipeline by Sigmoid Pharma Ltd., H1 2014 147
Colorectal Cancer - Pipeline by Intezyne, Inc, H1 2014 148
Colorectal Cancer - Pipeline by Igenica, Inc., H1 2014 149
Colorectal Cancer - Pipeline by Selvita S.A, H1 2014 150
Colorectal Cancer - Pipeline by Eddingpharm, H1 2014 151
Colorectal Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2014 152
Colorectal Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 153
Colorectal Cancer - Pipeline by Phosplatin Therapeutics, H1 2014 154
Colorectal Cancer - Pipeline by Vaxeal Holding SA, H1 2014 155
Colorectal Cancer - Pipeline by Oncobiologics, Inc., H1 2014 156
Colorectal Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2014 157
Colorectal Cancer - Pipeline by LivTech, Inc., H1 2014 158
Colorectal Cancer - Pipeline by Avipep Pty Ltd, H1 2014 159
Colorectal Cancer - Pipeline by Tactic Pharma, LLC, H1 2014 160
Colorectal Cancer - Pipeline by Kadmon Corporation, LLC, H1 2014 161
Colorectal Cancer - Pipeline by Targovax AS, H1 2014 162
Colorectal Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2014 163
Colorectal Cancer - Pipeline by AbbVie Inc., H1 2014 164
Colorectal Cancer - Pipeline by Precision Biologics, Inc., H1 2014 165
Colorectal Cancer - Pipeline by ImmunNovative Developments SL, H1 2014 166
Colorectal Cancer - Pipeline by Oncology Research International Limited, H1 2014 167
Colorectal Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 168
Colorectal Cancer - Pipeline by TARGETOME, H1 2014 169
Colorectal Cancer - Pipeline by Solvotrin Therapeutics Ltd, H1 2014 170
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2014 171
Assessment by Monotherapy Products, H1 2014 172
Assessment by Combination Products, H1 2014 173
Number of Products by Stage and Target, H1 2014 176
Number of Products by Stage and Mechanism of Action, H1 2014 182
Number of Products by Stage and Route of Administration, H1 2014 187
Number of Products by Stage and Molecule Type, H1 2014 190
Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2014 484
Colorectal Cancer - Dormant Projects, H1 2014 590
Colorectal Cancer - Dormant Projects (Contd..1), H1 2014 591
Colorectal Cancer - Dormant Projects (Contd..2), H1 2014 592
Colorectal Cancer - Dormant Projects (Contd..3), H1 2014 593
Colorectal Cancer - Dormant Projects (Contd..4), H1 2014 594
Colorectal Cancer - Dormant Projects (Contd..5), H1 2014 595
Colorectal Cancer - Dormant Projects (Contd..6), H1 2014 596
Colorectal Cancer - Dormant Projects (Contd..7), H1 2014 597
Colorectal Cancer - Dormant Projects (Contd..8), H1 2014 598
Colorectal Cancer - Dormant Projects (Contd..9), H1 2014 599
Colorectal Cancer - Dormant Projects (Contd..10), H1 2014 600
Colorectal Cancer - Discontinued Products, H1 2014 601
Colorectal Cancer - Discontinued Products (Contd..1), H1 2014 602
Colorectal Cancer - Discontinued Products (Contd..2), H1 2014 603

List of Figures
Number of Products under Development for Colorectal Cancer, H1 2014 31
Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2014 32
Number of Products under Development by Companies, H1 2014 33
Number of Products under Investigation by Universities/Institutes, H1 2014 44
Comparative Analysis by Clinical Stage Development, H1 2014 48
Comparative Analysis by Early Stage Products, H1 2014 49
Assessment by Monotherapy Products, H1 2014 172
Assessment by Combination Products, H1 2014 173
Number of Products by Top 10 Target, H1 2014 174
Number of Products by Stage and Top 10 Target, H1 2014 175
Number of Products by Top 10 Mechanism of Action, H1 2014 180
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 181
Number of Products by Top 10 Route of Administration, H1 2014 186
Number of Products by Stage and Top 10 Route of Administration, H1 2014 187
Number of Products by Top 10 Molecule Type, H1 2014 188
Number of Products by Stage and Top 10 Molecule Type, H1 2014 189

Companies Mentioned
Amgen Inc.
Adherex Technologies Inc.
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Genentech, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Oxford BioMedica plc
Aposense Ltd.
Novartis AG
Aphios Corporation
Astellas Pharma Inc.
CK Life Sciences Int'l., (Holdings) Inc.
Eisai Co., Ltd.
Nippon Kayaku Co., Ltd.
Pfizer Inc.
Astex Pharmaceuticals, Inc.
Taiho Pharmaceutical Co., Ltd.
Teva Pharmaceutical Industries Limited
Bayer AG
Advaxis, Inc.
4SC AG
EntreMed, Inc.
Celldex Therapeutics, Inc.
Enzo Biochem, Inc.
Immunomedics, Inc.
Idera Pharmaceuticals, Inc.
MEI Pharma, Inc.
Compugen Ltd.
Critical Outcome Technologies Inc.
CytRx Corporation
Regeneron Pharmaceuticals, Inc.
Dendreon Corporation
LG Life Sciences, Ltd.
Jiangsu Hengrui Medicine Co., Ltd.
Panacea Biotec Limited
CrystalGenomics, Inc.
Microbio Co., Ltd.
Rexahn Pharmaceuticals, Inc.
Morphotek, Inc.
Isarna Therapeutics GmbH
Chipscreen Biosciences Ltd
CIMAB S.A.
Supratek Pharma Inc.
Fusion Antibodies Ltd
Oxford BioTherapeutics Ltd
Multimmune GmbH
Nerviano Medical Sciences S.r.l.
Glycotope GmbH
TheRyte Ltd.
Celator Pharmaceuticals, Inc.
Arisaph Pharmaceuticals, Inc.
Cellectis S.A.
MacroGenics, Inc.
Boston Biomedical, Inc.
PLx Pharma Inc.
DanDrit Biotech A/S
Merrimack Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Jennerex Biotherapeutics, Inc.
MolMed S.p.A.
Etubics Corporation
Xcovery, Inc.
Quintessence Biosciences, Inc.
WntResearch AB
3-V Biosciences, Inc.
Phenomenome Discoveries, Inc.
Interprotein Corporation
Zyngenia, Inc.
Recepta Biopharma S.A.
ISU ABXIS Co.,Ltd.
Pepscan Therapeutics
NuCana BioMed Limited
KAEL-GemVax Co., Ltd.
Otsuka Holdings Co., Ltd.
XBiotech USA, Inc.
Wellstat Biologics Corporation
Regulon Inc.
Gradalis Inc.
Mabion SA
SentoClone International AB
Sigmoid Pharma Ltd.
Intezyne, Inc
Igenica, Inc.
Selvita S.A
Eddingpharm
PsiOxus Therapeutics, Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Phosplatin Therapeutics
Vaxeal Holding SA
Oncobiologics, Inc.
IMPACT Therapeutics, Inc.
LivTech, Inc.
Avipep Pty Ltd
Tactic Pharma, LLC
Kadmon Corporation, LLC
Targovax AS
Shanghai Henlius Biotech Co., Ltd.
AbbVie Inc.
Precision Biologics, Inc.
ImmunNovative Developments SL
Oncology Research International Limited
AlphaMab Co., Ltd
TARGETOME
Solvotrin Therapeutics Ltd
CCRP Therapeutics GmbH

Read the full report:
Colorectal Cancer - Pipeline Review, H1 2014

http://www.reportbuyer.com/pharma_healthcare/diseases/colorectal_cancer_pipeline_review_h1_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and KMPH. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.